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Abstract Prostate cancer remains a significant health
concern for men in the USA as it is a leading cancer
diagnosis and a cause of death. With the use of prostate-
specific antigen for screening, a stage migration has oc-
curred with an increase in the number of men diagnosed
with early-stage disease. The optimal primary manage-
ment of these men is evolving, but despite adequate local
treatment a significant percentage will develop either
biochemical or clinical evidence of recurrent disease.
Several criteria for risk stratification have been devel-
oped, thus, improving the ability to identify a high-risk
population. Small studies have been reported demon-
strating the feasibility of neoadjuvant or adjuvant che-
motherapy in conjunction with either radiation or
radical prostatectomy in this high-risk population, and
large phase III studies are ongoing. With the advent of
life-prolonging chemotherapy in the hormone-refractory
setting, attention must now also be given to early-stage
disease so as to develop multi-modality approaches with
the hope of increasing survival and ultimately providing
a cure.
Keywords Prostate cancer Æ Adjuvant
therapy Æ Neoadjuvant therapy Æ Multimodality
therapy Æ Chemotherapy
Introduction
In 2005, an estimated 230,090 men will be diagnosed
with prostate cancer and 30,350 will die secondary to
their disease [24]. Radical prostatectomy and radiation
therapy can be curative for many men with early-stage
disease, but a portion will experience relapse following
local therapy. Medical or surgical castration remains the
initial treatment of choice for men who present with or
develop metastatic disease. While the majority of these
patients will initially respond to androgen deprivation,
the duration of their response is only in the order of 18–
24 months [10, 16]. After progressing to androgen
independence, median survival is approximately 16–
18 months [36, 48, 51] and the majority of these patients
die of metastatic prostate cancer.
Historically, chemotherapy has not been viewed as
having a crucial role in the management of patients with
prostate cancer. The failure of a variety of regimens to
show significant responses and survival benefits in the
hormone-refractory population led many researchers to
believe that chemotherapy should not be considered
standard for advanced prostate cancer patients, with the
exception of participation in clinical trials for select
patients [49]. This opinion began to change with the
inclusion of quality-of-life endpoints in clinical trials
evaluating the utility of chemotherapy for men with
androgen-independent prostate cancer. Two random-
ized phase III trials have shown improved pain control
with mitoxantrone and either prednisone or hydrocor-
tisone over steroids alone in this patient population, but
these studies did not demonstrate significant impacts on
overall survival [26, 50].
Building on these findings, efforts have focused on
utilizing newer agents. Of the cytotoxic therapies, tax-
anes have been extensively investigated with particular
attention given to docetaxel, which targets the cellular
microtubules. The drug binds to tubulin, stabilizes
microtubule formation and inhibits depolymerization.
Phase II trials have demonstrated prostate-specific
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antigen (PSA) declines of >50% in 38–46% of hor-
mone-refractory patients treated with 75 mg/m2 of do-
cetaxel every 3 weeks, and measurable disease responses
occurred in 28–60% of patients [17, 38]. Weekly sched-
ules have also been investigated and reports suggest that
they have significant levels of activity [2, 4]. Hematologic
toxicity was a concern in all of these trials, and grade 3
or 4 neutropenia occurred in 43% of patients who re-
ceived docetaxel once every 3 weeks. Although the fre-
quency of neutropenia was less with weekly regimens,
neutropenic fever and hospitalization were rare events
with either dosing schedule.
These encouraging phase II data led to two phase III
randomized trials comparing docetaxel versus mitoxan-
trone regimens in men with androgen-independent
prostate cancer. The Southwest Oncology Group
(SWOG) demonstrated in SWOG 9916 a significantly
improved median survival of 18 months with the com-
bination of docetaxel and estramustine administered
every 3 weeks as compared to 15 months with mito-
xantrone and prednisone. Time to progression was also
superior for docetaxel plus estramustine: 6 months ver-
sus 3 months for mitoxantrone and prednisone [36]. The
second study, TAX 327, also showed superiority of do-
cetaxel over mitoxantrone. Docetaxel, when given
75 mg/m2 every 3 weeks with a daily dosage of predni-
sone, provided median survival of 18.9 months. These
results were statistically significant compared with the
16.5-month median survival in patients who received
mitoxantrone and prednisone. A third arm utilized
30 mg/m2 of docetaxel which was given weekly for
5 weeks of 6-week cycles, and the median survival of
17.4 months was not statistically significant compared
with the mitoxantrone arm [51]. From a quality-of-life
standpoint, the 3-week docetaxel regimen resulted in
significantly improved pain control over mitoxantrone.
These studies are important in that they are the first to
report a survival advantage as well as palliative benefits
with chemotherapy in hormone-refractory prostate
cancer, thus establishing docetaxel as the standard
therapy in this setting, and laying the foundation for
investigating chemotherapy in earlier stages of prostate
cancer.
Clinically localized prostate cancer
With the development of PSA-based early detection
strategies for prostate cancer, a stage migration has
occurred with a resultant increase in the number of
men with clinically localized prostate cancer [21]. Five-
year survival rates in men with prostate cancer have
significantly improved over the last few decades, per-
haps due to earlier detection and improvements of local
control [23]. However, local therapy does not cure all
patients with localized disease, as shown in a pooled
analysis of men who received radiation where 34%
exhibited biochemical recurrence at 5 years [47]. In
large reported series of men who underwent radical
prostatectomy, 15–31% went on to exhibit biochemical
evidence of recurrent disease [25, 40, 41]. Specifically,
Pound et al. [40] reported that 34% of men with a
rising PSA after radical prostatectomy were found to
have metastatic disease at a median of 8 years; more-
over, once metastases were detected they had a median
time to death of 5 years. Therefore, while a large
portion of men are essentially cured of their prostate
cancer by local therapy, a segment of patients with
clinically localized disease are at high risk for future
relapse and possibly death from their disease.
Experience with other solid tumors including breast,
lung and colon cancer suggests that even modestly active
systemic chemotherapy can have curative potential when
administered in the adjuvant setting. In prostate cancer,
efforts have begun to evaluate the role of systemic
therapy in patients with high-risk localized or locally
advanced disease. For obvious reasons, the most studied
treatment option has been androgen ablation. Several
trials have been performed to evaluate the role of neo-
adjuvant and adjuvant hormonal therapy in combina-
tion with radical prostatectomy or radiation therapy.
Neoadjuvant hormonal therapy prior to radical prosta-
tectomy for patients with localized or locally advanced
prostate cancer has resulted in decreased positive margin
rates but with no survival benefit [8, 46, 52]. Alterna-
tively, men who are found to have lymph node metas-
tases at radical prostatectomy have been shown to have
a survival benefit and a decreased risk of recurrence with
immediate as opposed to delayed adjuvant hormonal
therapy [32].
Trials evaluating radiation therapy in conjunction
with androgen deprivation have shown benefits with the
addition of hormonal therapy. In a European Organi-
zation for Research and Treatment of Cancer (EORTC)
study, men with locally advanced prostate cancer had
improved overall and disease-free survival with radia-
tion combined with 3 years of androgen deprivation
versus radiation alone [6]. In this study, 5-year disease-
free survival was 62% in the combination arm, and
distant metastases accounted for the majority of recur-
rences suggesting that androgen deprivation is not suf-
ficient systemic therapy to prevent metastatic disease.
Prostate cancer is thought to be heterogeneous in
composition, with both androgen-dependent and
androgen-independent clones, and hormonal manipula-
tions may select for insensitive cells that remain viable
and capable of uncontrolled growth. This concept is
supported by the observed suboptimal outcome with
adjuvant hormones and would argue for the need to
investigate early chemotherapy. While more progress is
needed, data from recent phase III trials demonstrate for
the first time that prostate cancer is not a chemoresistant
disease, thus opening the door to a new era of investi-
gations in the setting of early-stage disease. Critical to
the success of this effort is the ability to identify high-
risk patient populations whose benefit from treatment




Until recently, stage and Gleason score have been the
backbone for risk prediction. PSA has also been incor-
porated into risk assessment, and several models and
nomograms have been developed that stratify patients
for risk of recurrence. Partin et al. [34] were the first to
combine these three characteristics so as to predict pre-
operatively the final pathologic stage and likelihood of
organ-confined prostate cancer. Serum PSA, pretreat-
ment biopsy Gleason score, and clinical stage each
independently predicted pathologic stage, but results
were improved by combining all three factors. This
model has been validated in retrospective analyses of
men treated with either radical prostatectomy or radia-
tion therapy [5, 31], and an updated version of the tables
has been published [35].
D’Amico et al. have utilized clinical characteristics to
risk-stratify patients by likelihood of biochemical recur-
rence at 5 years [12] and 10 years [11] following local
therapy. Results suggest that patients can be stratified by
pretreatment PSA, biopsy Gleason score and 1992 AJCC
T stage in terms of risk of biochemical recurrence at
5 years. Low-risk patients (stage T1c or T2a, and
PSA £ 10 ng/ml, and Gleason score £ 6) have an esti-
mated 5-year biochemical failure-free rate of >80%.
Intermediate-risk patients (stage T2b, PSA 11–20 ng/ml,
Gleason score 7) have failure-free rates of about 60%,
and high-risk patients (stage >T2c or PSA >20 ng/ml
or Gleason score >7) have an estimated rate of <40%.
Kattan et al., using similar clinical characteristics,
have developed a continuous probability nomogram to
predict likelihood of biochemical recurrence following
primary therapy for localized prostate cancer. While
risk-stratification models are easy for clinicians to
remember and apply to patients, these probability no-
mograms place patients on a continuous spectrum of
risk recurrence rather than in heterogeneous risk groups,
potentially resulting in a more accurate assessment.
Pretreatment nomograms for radiation therapy [29] and
radical prostatectomy [27] as well as a postprostatec-
tomy nomogram [28] have been developed to predict
freedom from recurrence. Both the pre- and postopera-
tive nomograms have been validated [18, 19]; further-
more, the preoperative nomogram was validated using a
large international dataset suggesting that the model is
accurate even in the setting of a heterogeneous patient
population [19].
Prostate-specific antigen kinetics, which have been
shown to be predictive of prostate cancer-specific mor-
tality in the hormone refractory setting [13], may also be
useful in identifying men with clinically localized disease
who are likely to die of their disease. A recent study
suggests that men with T1c or T2 disease who have a
PSA velocity >2.0 ng/ml in the year prior to treatment,
are at significantly increased risk of biochemical disease
recurrence, death from prostate cancer, and death from
any cause [14].
These tools are useful to clinicians when counseling
their patients and for risk stratification in clinical trials.
However, consideration must be given to the fact that
they have not been tested prospectively.
Adjuvant chemotherapy
By comparison with other solid tumors, multimodality
approaches to early-stage prostate cancer are still in
their infancy. Several trials dating back to the 1970s and
1980s have attempted to address this issue. With an
adjuvant approach, patient selection is improved since
treatment decisions are based on accurate pathologic
surgical staging, and the number of patients who
unnecessarily receive cytotoxic chemotherapy is reduced.
Between 1978 and 1985, the National Prostate Can-
cer Project (NPCP) initiated two protocols which were
designed to test the efficacy and toxicity of adjuvant
chemotherapy following radical prostatectomy (Proto-
col 900) or definitive radiation (Protocol 1000) [43–45].
Men at high risk of recurrence were randomized to re-
ceive 2 years of either cyclophosphamide or estramus-
tine versus observation alone following primary therapy.
Patients who received cyclophosphamide did not have
improved progression-free survival relative to the
observation arm in either the prostatectomy or radiation
protocol. However, node-positive patients treated with
radiation and estramustine had a 60% recurrence rate
versus 81% in the observation arm (P<0.05). In parti-
cular, stage C patients who underwent prostatectomy
and patients with grade 3 tumors, regardless of local
therapy, benefited from estramustine. While this is the
largest study published on the investigation of the use of
adjuvant chemotherapy in high-risk disease, the trial was
underpowered to reliably answer the question regarding
efficacy of systemic therapy in this population.
The remaining published trials of adjuvant chemo-
therapy in patients with high-risk disease suffer from
small sample sizes and methodological limitations (Ta-
ble 1). One of the most recent trials suggesting benefits
of early chemotherapy is a study by Wang et al. [53] who
evaluated adjuvant mitoxantrone in men with advanced
prostate cancer, a number of whom had locally ad-
vanced disease. Patients were randomized to receive ei-
ther hormonal therapy alone consisting of luteinizing
hormone-releasing hormone agonist and flutamide or
hormonal therapy with mitoxantrone. No advantage to
mitoxantrone was identified in the metastatic popula-
tion. However, patients with localized disease, who re-
ceived hormonal therapy and mitoxantrone, had
improved median survival over patients on hormonal
therapy alone [53].
Collectively, however, these studies are too small to
draw firm conclusions regarding the effects of adjuvant
chemotherapy on survival in men with high-risk prostate
cancer, but they suggest that multimodal therapy is fea-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and conducted prospective, randomized, controlled trials
will questions regarding the utility of adjuvant chemo-
therapy be adequately answered.
Neoadjuvant chemotherapy
Neoadjuvant chemotherapy has also been actively
investigated (Table 2), and this approach has several
benefits. Micrometastatic disease, which is present at the
time of diagnosis and is a source of potential failure for
local treatment, is treated without delay. Locally ad-
vanced tumors, if responsive to chemotherapy, are re-
duced in size such that they are more amenable to local
therapy. Postoperative pathologic specimens may be
collected and analyzed to confirm efficacy of treatment.
Such an approach may also provide a model for efficient
drug development, with opportunities to evaluate tar-
geted therapies as well as improve understanding of
mechanisms of response and resistance to treatment
utilizing human specimens. Several groups have pub-
lished results of trials evaluating neoadjuvant chemo-
therapy with or without androgen ablation for clinically
localized prostate cancer. However, these studies are
difficult to compare due to the small numbers of patients
included, the differences in eligibility criteria, and the
variety of chemotherapeutic agents and regimens uti-
lized.
Many of the high-risk prostate cancer neoadjuvant
trials have included estramustine combined with other
chemotherapeutic agents [9, 30, 37]. Thromboembolic
events related to estramustine were reported in each of
these studies. Positive surgical margin rates have been
favorable, and clinical downstaging of patients after
neoadjuvant treatment prior to prostatectomy has been
reported [9, 30]. However, residual disease was identified
in post-prostatectomy specimens of all patients included
in these trials.
Two groups have reported results of neoadjuvant
estramustine-based chemotherapy prior to radiotherapy.
Zelefsky et al. [54] treated men with unfavorable risk
profiles with two cycles of neoadjuvant estramustine/
vinblastine followed by a third cycle given concurrently
with radiation, while Ben-Josef et al. [3] reported results
of two cycles of neoadjuvant estramustine and etoposide
followed by concurrent estramustine and three-dimen-
sional conformal radiotherapy. Chemotherapy and
radiation-related toxicity profiles were reasonable;
however, thromboembolic complications attributable to
estramustine were reported by both investigators.
Two groups have reported results of single-agent
docetaxel given either for 6 months [33] or 6 weeks [15]
prior to prostatectomy. In the study by Dreicer et al.
[15], residual disease was identified in all prostatectomy
specimens and 89% of the specimens had extracapsular
extension. Hussain et al. [22] treated patients with high-
risk disease with neoadjuvant docetaxel and estramus-
tine prior to either radiation or radical prostatectomy.
Among patients who underwent radical prostatectomy,
70% had negative surgical margins but none achieved
pathologic complete remission. Preradiotherapy pros-
tate biopsies were negative in 2 of 11 patients.
These studies are all too small to draw conclusions
regarding the efficacy of neoadjuvant chemotherapy.
However, like the adjuvant studies they do demonstrate
feasibility and acceptability among patients who were
administered chemotherapy in the early-disease setting.
Aside from some serious thromboembolic complications
likely due to estramustine, chemotherapy was overall
well tolerated. Surgery following chemotherapy largely
did not result in an increased rate of significant surgical
complications. Clark et al. [9] noted a desmoplatic
reaction around the prostate, potentially making surgery
more difficult. They were nonetheless successfully able to
perform radical prostatectomies on all patients included
in their study. One should note that PSA response does
not appear to be as significant in the early stages of
disease as believed in hormone-refractory populations.
Although several of the neoadjuvant studies noted sig-
nificant PSA responses prior to primary treatment,
residual tumor was identified in all postsurgical speci-
mens. It is unclear why no pathological complete re-
sponses were observed. Similarly it is not clear how to
assess response/efficacy in phase II trials of neoadjuvant
chemotherapy and what the most appropriate endpoints
are. In other neoplasms such as bladder cancer, a com-
plete pathologic response is possible following neoad-
juvant chemotherapy and has been shown to be a useful
prognostic factor [20].
Phase III trials of adjuvant and neoadjuvant
chemotherapy
Cooperative groups have led the way by initiating phase
III trials to address the role of systemic therapy in early-
stage high-risk prostate cancer. Several ongoing and
planned protocols are listed in Table 3. These are large
trials that are adequately powered to detect meaningful
differences in survival with the addition of systemic
chemotherapy.
The first is an important trial led by the Southwest
Oncology Group (S9921). Eligible men must have
Gleason scores 8–10, pathologic stage ‡pT3b, or nodal
involvement or Gleason score 7 and positive margins.
Following radical prostatectomy, patients are random-
ized to combined androgen blockade for 2 years or
mitoxantrone and prednisone for six cycles and com-
bined androgen blockade for 2 years. Patients with po-
sitive surgical margins are permitted to receive adjuvant
radiation. A total of 1,360 enrolled subjects are needed
to achieve 92% power to detect a 30% increase of
median survival in the chemotherapy arm by a one-sided
t test and a significance level of 0.05.
A phase III randomized trial investigating the role of
neoadjuvant chemotherapy is planned by Cancer and
Leukemia Group B (CALGB 90203). Eligible patients










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































following prostatectomy based on the Kattan nomogram
and a life expectancy of ‡10 years. Patients will be ran-
domized to radical prostatectomy alone or neoadjuvant
estramustine and docetaxel followed by radical prosta-
tectomy. Planned accrual is 750 men with a 90% power
to detect a 36% decrease in 5-year recurrence rates,
which is the primary endpoint of the study.
An industry-sponsored trial is also being planned to
evaluate the role of early versus delayed treatment,
consisting of androgen deprivation alone or with do-
cetaxel, in a high-risk population following radical
prostatectomy.
Conclusions
Improvements of systemic therapy for prostate cancer
over the past decade have opened the door for active
investigation of novel and effective treatments in all
stages of the disease. One of the major results of this
progress is the initiation of several large randomized
clinical trials in early-stage disease. This approach has
been enriched by improvements in risk prediction and
the recognition that outcome improvement, much like in
other cancers, is dependent on multimodal therapy.
Such approaches are gaining increasing acceptability
among patients and physicians. Defeating prostate
cancer will require solid commitment to continued
clinical/translational research in this area and to offer
access to clinical trials to all appropriate patients.
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